[Anti-VEGF: a new therapeutic option in hereditary hemorrhagic telangiectasia]

Presse Med. 2013 Apr;42(4 Pt 1):385-7. doi: 10.1016/j.lpm.2012.11.009. Epub 2013 Feb 18.
[Article in French]
No abstract available

Publication types

  • Editorial

MeSH terms

  • Activin Receptors, Type II / genetics
  • Adolescent
  • Adult
  • Aged
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antigens, CD / genetics
  • Bevacizumab
  • DNA Mutational Analysis
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Endoglin
  • Female
  • Humans
  • Injections, Intravenous
  • Male
  • Middle Aged
  • Prospective Studies
  • Receptors, Cell Surface / genetics
  • Smad4 Protein / genetics
  • Telangiectasia, Hereditary Hemorrhagic / diagnosis
  • Telangiectasia, Hereditary Hemorrhagic / drug therapy*
  • Telangiectasia, Hereditary Hemorrhagic / genetics
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors*
  • Young Adult

Substances

  • Antibodies, Monoclonal, Humanized
  • Antigens, CD
  • ENG protein, human
  • Endoglin
  • Receptors, Cell Surface
  • SMAD4 protein, human
  • Smad4 Protein
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab
  • ACVRL1 protein, human
  • Activin Receptors, Type II